Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 5/20 | 0.64 |
| ▸ | THRB | P10828 | 10/20 | 0.49 |
| ▸ | THRA | P10827 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 1/20 | 0.49 |
| ▸ | GABRD | O14764 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379411 | 0.99 | PCNA (0.66) | PCNATHRBTHRALMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28229787 | 0.97 | PCNA (0.64) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL5501440 | 0.82 | PCNA (0.70) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL10521395 | 0.81 | THRB (0.70) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL34943 | 0.81 | PCNA (0.71) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL31368013 | 0.81 | PCNA (0.71) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL4439595 | 0.80 | PCNA (0.97) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL30586189 | 0.80 | THRB (0.46) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL2679290 | 0.80 | PCNA (0.70) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL10884352 | 0.80 | PCNA (0.59) | PCNATHRBTHRALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| CN-216879287-U | Levo-thyroxine production protection device | 天津九海医药科技有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-113636965-A | High penetration composition and application thereof | 于崇曦 | 2021-11-12 | — | — | CN | disclosed |
| CN-107320732-B | High penetration composition and application thereof | 于崇曦 | 2021-09-07 | — | — | CN | disclosed |
| CN-108191846-B | High penetration composition and application thereof | 于崇曦 | 2021-08-20 | — | — | CN | disclosed |
| CN-111808011-A | High penetration composition and application thereof | 于崇曦 | 2020-10-23 | — | — | CN | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| CN-101106981-A | Oxygen-impervious packaging and method for storing thyroid hormone | KING PHARMACEUTICALS RES & DEV (US) | 2008-01-16 | — | — | CN | disclosed |
| EP-1474103-A1 | LEVOTHYROXINE COMPOSITIONS AND METHODS | King Pharmaceuticals, Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003070217-A1 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003061557-A2 | LEVOTHYROXINE PHARMACEUTICAL COMPOSITIONS, METHODS OF MAKING AND METHODS OF ADMINISTRATION | KING PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003028624-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | PCNA 381/4885THRB 4053/4885THRA 2390/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | PCNA 381/4885THRB 4053/4885THRA 2390/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | PCNA 580/4885THRB 3974/4885THRA 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.